New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2013
13:38 EDTSHPG, BMY, BIIBUnclear if pipeline alone can restore Bristol's growth, WSJ says
With Bristol-Myers' (BMY) losing Plavix patent exclusivity, the company took a 17% hit in revenues in 2012, and is now counting on new drugs like Eliquis and late-stage drugs aiming to treat cancer, diabetes and hepatitis C to restore growth, says the Wall Street Journal. However, "it remains unclear whether new drugs alone will be enough to restore growth," says WSJ, adding that in recent months Bristol has studied the possibility of Biogen Idec (BIIB) Shire (SHPG) as possible acquisition targets. Reference Link
News For BMY;SHPG;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 19, 2014
08:51 EDTBIIBBiogen drops 2% after Roche discontinues Alzheimer drug trial
Shares of Biogen (BIIB) are moving lower after Roche (RHHBY) announced the discontinuation of its Alzheimer's drug gantenerumab, which was in Phase III testing. Analysts at Wells Fargo said Roche's trial failure adds risk to Biogen's potential treatment of Alzheimer's. Shares of Biogen are down $8.20 to $345.50 in pre-market trading.
December 17, 2014
11:28 EDTSHPGNPS Pharmaceuticals calls active on Shire considering bid report
Subscribe for More Information
11:13 EDTSHPGShire considering bid for NPS Pharmaceuticals, Bloomberg reports
Subscribe for More Information
10:49 EDTSHPGNPS Pharmaceuticals jumps 12%, halted after report of potential Shire bid
Shire (SHPG) has NPS Pharmaceuticals (NPSP) on the top of its list of potential takeover targets, but is also said to be considering other targets, according to Bloomberg.
10:47 EDTSHPGNPS Pharmaceuticals said to be on top of Shire takeover list, Bloommberg says
Subscribe for More Information
10:47 EDTSHPGNPS halted for volatility after Bloomberg says Shire considers bid
Subscribe for More Information
December 16, 2014
08:47 EDTBMYHemispherx Ampligen provides anti-tumor activity
Subscribe for More Information
December 12, 2014
08:01 EDTBIIBPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 11, 2014
08:57 EDTSHPGLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
06:29 EDTSHPGShire CEO sees no immediate need to spend break-up fee, Reuters reports
Subscribe for More Information
December 10, 2014
06:08 EDTBMYBristol-Myers partners with Ono Pharma and Kyowa Hakko Kirin for oncology trial
Subscribe for More Information
December 9, 2014
16:35 EDTBMYBristol-Myers raises dividend to 37c per share from 36c per share
Subscribe for More Information
12:22 EDTBIIB, SHPGPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
10:23 EDTSHPGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:25 EDTBMYBristol-Myers data positive, says BMO Capital
Subscribe for More Information
05:38 EDTSHPGShire downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
December 8, 2014
13:32 EDTBMYPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
05:53 EDTBMYStocks with implied volatility movement; BSX BMY
Subscribe for More Information
December 7, 2014
14:10 EDTBMYAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:06 EDTBMYBMY announces positive results in Phase 1b trial evaluating Opdivo
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use